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ajor depressive disorder (MDD) is a serious,
debilitating illness that affects persons of all ages,races,
and socioeconomic backgrounds. The Institute of
Medicine (IOM) report, Priority Areas for National
Action: Transforming Health Care Quality, lists major
depression among 20 priority areas for health care qual-
ity improvement, identifying the aim “to improve
national rates of diagnosis and appropriate treatment of
major depression.”
1 MDD occurs in up to one in eight
individuals during their lifetime, making it one of the
most prevalent of all medical illnesses.According to the
Diagnostic and Statistical Manual-Fourth Edition Text
Revision (DSM-IV TR),
2 the point prevalence rates for
MDD are approximately 2.3% to 3.2% in men and 4.5%
to 9.3% in women,with a lifetime risk for developing an
episode of 7% to 12% for men and 20% to 25% for
women.Depression currently ranks fourth for disability-
adjusted life-years worldwide
3 and is projected to jump
to second global leading cause of disability by 2020.
The recent National Institute of Mental Health-funded
Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study showed that remission rates are modest
even after two state-of-the-art,diligently delivered treat-
ment steps with the support of depression care special-
ists.
4-6 Even following four steps,there still remain a large
percentage of patients who do not benefit.
7
Treatment-resistant depression
Treatment-resistant depression (TRD) is a common prob-
lem in the treatment of MDD,yet little agreement exists
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Major depressive disorder (MDD) is an often chronic,
recurrent illness affecting large numbers of the general
population. In recent years, the goal of treatment for
MDD has moved from mere symptomatic response to
that of full remission (ie, minimal/no residual symptoms).
The recent Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) trial showed that even with system-
atic measurement-based treatment, approximately one
third of patients reach full remission after one treatment
trial, with only two thirds reaching remission after four
treatment trials. Treatment-resistant depression (TRD) is
therefore a common problem in the treatment of MDD,
with 60% to 70% of all patients meeting the criteria for
TRD. Given the huge burden of major depressive illness,
the low rate of full recovery remains suboptimal. The fol-
lowing article reports on some current treatment strate-
gies available to improve rates of, and to sustain, remis-
sion in MDD. 
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:377-384.
Keywords: remission; treatment-resistant depression; function 
Author affiliations: Mood Disorders Program, Department of Psychiatry,
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA  
Address for correspondence: Madhukar H. Trivedi, MD, Professor of Psychiatry,
Betty Jo Hay Distinguished Chair in Mental Health, Director, Mood Disorders
Program, University of Texas Southwestern Medical Center at Dallas, 5323 Harry
Hines Blvd, Dallas, TX 75390-9119, USA
(e-mail: madhukar.trivedi@utsouthwestern.edu)
Mabout either the definition of TRD or evidence-based
options for treatment.According to Rush et al,treatment
resistance falls on a continuum.
8 Modest resistance may
include an inadequate response to a single antidepressant
trial, whereas greater resistance refers to failure of two
monotherapy trials or one or more augmentation trials.
Various staging schemes have been proposed for TRD,
taking into consideration greater or lesser resistance
according to the number of adequately delivered trials (in
terms of dose,duration,and adherence) given to patients
with properly diagnosed disease.
9,10 Souery et al proposed
an operational definition for TRD as the failure to
respond to two adequate trials of different classes of anti-
depressants.
11 Similarly,Sackeim et al proposed that clini-
cally significant treatment resistance is present if depres-
sion has not benefited from at least two adequate trials of
medications from different classes in the current episode.
12
Traditionally,treatment resistance has focused on nonre-
sponse (eg, minimal or no improvement on drug ther-
apy).From the perspective of clinicians and patients,not
achieving full remission represents a significant burden
and therefore full remission should be the optimal goal.
13
Partial response refers to the situation wherein an indi-
vidual has responded to antidepressant treatment but still
has significant residual symptoms that interfere with
work,family,and social activities.
Remission as the goal of treatment
The chronic nature of MDD contributes to difficulty in
achieving the goal of remission—ie, full return to pre-
morbid functioning between episodes. Residual symp-
toms of depression (including low mood,early insomnia,
weight loss,and hopelessness) are often accompanied by
significant occupational and psychosocial dysfunction,as
well as being associated with early relapse and increased
recurrence rates.
14,15There is considerable evidence that
even with treatment, residual symptoms often persist,
leading to psychosocial dysfunction,
16-18 and the longer a
patient remains symptomatic,the lower the chances of a
complete recovery.
17
Treatment strategies to achieve remission
Pharmacological treatments
Initial treatment - monotherapy versus combination
therapy
Evidence to date suggests that the longer it takes to get
to remission (ie,the more treatment trials required),the
greater the risk of treatment resistance.Consensus opin-
ion therefore suggests that aggressive initial treatment is
the most appropriate strategy. Medications recom-
mended for initial treatment of a major depressive
episode (MDE) include selective serotonin reuptake
inhibitors (SSRIs—fluoxetine, paroxetine, sertraline,
citalopram,and escitalopram),serotonergic noradrener-
gic reuptake inhibitors (SNRIs—venlafaxine and dulox-
etine),bupropion,and mirtazapine.All these antidepres-
sants are considered similar in regard to efficacy (Level
A data—evidence derived from randomized,controlled
clinical trials),with treatment selection based upon indi-
vidual patient characteristics (comorbidities,concomitant
medication,treatment history) and patient preference.
In a soon to be published update on the Texas
Medication Algorithm Project (TMAP) for MDD, the
expert panel convened recommends that a trial of at least
6 weeks' duration on the maximum tolerated antidepres-
sant dose be carried out before moving to the next treat-
ment trial (algorithm stage).During the course of treat-
ment with an individual antidepressant, the panel
recommends that clinicians monitor patients based on
certain time points in the clinical trial known as critical
decision points (CDP) in the algorithm.CDPs use symp-
tom-based rating scales to measure changes in depressive
symptoms (eg, the Quick Inventory of Depressive
Symptomatology—QIDS
19-21),side effects (eg,Frequency
and Intensity of Side Effect Rating Scale—FIBSER
22),
and tolerability,to help the clinician and patient make
decisions regarding the algorithm at specified time points.
This revised set of algorithm recommendations reflects
the most current available research evidence for treat-
ment of MDD in combination with the consensus of
leading experts in this area.
Combination treatments 
The low remission rates with any initial monotherapy
and the modest additional remission achieved with a sub-
sequent switch or augmentation medication step suggest
the potential need for using medication combinations at
the outset of treatment of MDD.Currently,combinations
of antidepressants are used in practice at the second or
subsequent steps when relapse occurs in the longer term,
or,in some cases,even acutely as a first step when speed
of effect is a clinical priority. Such combinations could
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or provide greater longer-term benefit if used as initial
treatments as compared with monotherapy. Our own
group is currently coordinating a large,NIMH-funded,
multisite study comparing two combination therapies
with monotherapy when used as initial treatments in the
current MDE in patients with chronic and recurrent
major depression.
The paradigm of using combination treatments is analo-
gous to treatment for other severe general medical con-
ditions (eg, cancer, congestive heart failure, malignant
hypertension, HIV, etc). That is, more vigorous initial
treatment efforts are implemented initially,rather than
using an extended trial-and-error,multistep approach to
isolate the single best medication or combination.
Furthermore,the likely higher remission rate with com-
binations may also reduce attrition during short-term and
longer-term treatments for MDD.Finally,antidepressant
medication combinations may have pharmacological
additive effects or create a broader spectrum of action in
short-term treatment.
Sequential treatment strategies
Over time, many different strategies have been devel-
oped in an effort to overcome the problem of partial or
nonresponse to treatment.These include augmentation
strategies,switching agents,combining antidepressants
(two medications or medication and psychotherapy),and
dual-action agents.
In terms of sequential treatment approaches,as yet there
are no randomized studies suggesting which specific
treatment sequence is best,and further studies are clearly
needed to evaluate the comparative efficacy and tolera-
bility of different approaches.Adaptive strategies to date
rely primarily on consensus-based,clinical decision-mak-
ing,rather than on innovative study designs that address
the identification of the best sequence for individual or
groups of patients.Traditional approaches have consid-
ered each step in the sequence as a new trial, but we
know that each treatment step builds on the previous
treatment,and that resistance to one step increases the
chances of resistance to subsequent steps. In addition,
despite patient and provider education,suboptimal med-
ication dosing and duration of exposure remain the
norm.
23-26 These difficulties herald the need for a para-
digm shift in how clinical decision-making is incorporated
into clinical practice and research study designs.
Switching,augmentation,and combination strategies
There is increasing evidence that augmentation and
switching are effective strategies after failure of an ade-
quate antidepressant treatment trial.In general,augmen-
tation is the preferred clinical choice when the patient is
showing at least a partial response to the primary antide-
pressant and the primary medication is well tolerated.In
contrast, switching is preferred when the patient has
shown no response to the initial antidepressant.In deter-
mining the choice of the switching agent,clinical consen-
sus suggests a trial with an antidepressant from a differ-
ent class than the first medication.However,there is now
evidence that switching from one SSRI to another SSRI
may be a reasonable strategy.
4 Furthermore, switching
from a medication to a depression-focused psychother-
apy,or vice versa,appears to produce comparable out-
comes.
27 In terms of augmentation, many agents have
been investigated with variable evidence of efficacy,
including lithium,
28-31 triiodothyronine (T3),
32,33 bus-
pirone,
6,34 atypical antipsychotics,
35,36 lamotrigine,
37,38
dopaminergic agonists,
39,40 pindolol,
41,42 and psychostimu-
lants,
43,44 as well as antidepressants with a different neu-
rochemical profile to the primary agent. Despite the
widespread use of these strategies,further supporting evi-
dence from placebo-controlled trials is still lacking.
45
Other novel targets are also being investigated including
melatoninergic receptor agonists,N-methyl D-aspartate
(NMDA), glucocorticoid, omega-3 fatty acids, novel
monoamine oxidase inhibitors,substance P,triple reup-
take inhibitors,
46 nicotinic acetylcholine receptor antago-
nists,and endocannabinoid receptor antagonists.
Nonpharmacological treatments
Other,nonpharmacological,treatments have also been
evaluated in terms of their potential as treatment options
in patients not responding to antidepressants.
Somatic treatments
There has been growing interest in the potential applica-
tion of vagus nerve stimulation (VNS) in the nonphar-
macological treatment of TRD.
47-53 In July 2005,the US
Food and Drug Administration approved VNS with an
indication for the adjunctive long-term treatment of
chronic or recurrent depression for adults refractory to
antidepressant drugs (with the recommendation that
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before using VNS).
Similarly, repetitive transcranial magnetic stimulation
(rTMS) has been studied as an adjunctive treatment for
drug-resistant MDD.
54-56 However, results so far have
been conflicting,a fact that may be related to variabil-
ity in stimulation parameters and small sample sizes,as
well as heterogeneity of concomitant drug treatments.
Larger trials are ongoing.Other novel neurostimulation
treatments with preliminary evidence of efficacy for
TRD include deep brain stimulation
57,58 and magnetic
seizure therapy.
59,60
There remains controversy within the field in terms of
the efficacy and safety of electroconvulsive therapy
(ECT) as a treatment modality.Following a meta-analy-
sis, a group of researchers in the United Kingdom
recently found that ECT is an effective short-term treat-
ment for depression,with some evidence suggesting that
ECT is more effective than pharmacotherapy.
61 However,
in a recent study,another group looked at ECT versus
pharmacotherapy as a treatment for relapse prevention,
finding that both treatments had limited efficacy with
more than half of patients experiencing relapse or drop-
ping out of the study.
62
Psychotherapy
Cognitive,interpersonal,and behavioral psychotherapy
have all been shown to be effective in the treatment of
depression,with results comparable to those found with
antidepressant medications in randomized controlled tri-
als.
63-65 Specifically, cognitive behavioral therapy (CBT)
appears to reduce residual symptoms in depression and
ultimately reduces the risk of relapse.
66-69 It has also been
suggested that combined treatment with antidepressant
medication and psychotherapy may be more effective than
either strategy alone.
70,71 However,others caution that the
advantage of combined treatment may be limited to treat-
ment of patients with more complex depressive disorders,
including characteristics such as comorbidity,chronicity,
treatment resistance,episodicity,and severity.
72
Strategies to sustain remission
Disease self-management
There is evidence that patient-focused interventions
rather than purely disease-focused interventions have a
more sustainable impact on outcomes.Disease self man-
agement is predicated on promoting patient self-manage-
ment and physician adherence to guidelines.
73 Despite the
fact that disease management has demonstrated its
potential for improving quality of care for an index dis-
ease,
74,75 few programs coordinate care among providers
or to manage health conditions unrelated to the index
disease.A growing body of evidence suggests that more
comprehensive,multifaceted innovations that simultane-
ously address health care provider practice,patient edu-
cation,and patient self-management tend to have more
compelling results.
76-78There is also a great need for pro-
grams working within, rather than outside of, primary
care,
79 where the majority of patients with depression are
actually seen.
Research suggests that applying a chronic care model to
depression care may result in better quality of care and
clinical outcomes.
79 Self-care and medical care are both
enhanced by effective collaboration among chronically
ill patients and health care providers.Self-care refers to
engaging in activities that promote health,adhering to
recommended treatment,self-monitoring of physical and
emotional status,and monitoring effects of the illness on
emotions and relationships.
79 Collaborative management
is care provided to strengthen and support self-care in
chronic illness,while assuring that effective medical,pre-
ventive, and health maintenance interventions occur.
Essential components of collaborative management
include:(i) identification of patient-defined problems;(ii)
targeting, goal-setting, and planning; (iii) creation of a
continuum of self-management training and support ser-
vices;and (iv) active and sustained follow-up.
79
Measurement-based care
Even in guideline-driven practice,clinical treatment of
depression is often associated with wide variations
among practitioners.Clinicians often change from one
antidepressant to another too quickly or,conversely,con-
duct an unnecessarily prolonged treatment trial with an
obviously unsuccessful medication or psychotherapy.
5,80
Practitioners also differ in how they assess the outcomes
of treatment (symptoms,function,side-effect frequency
and burden),with global judgments often used instead of
specific symptom assessments,even though the former
are less accurate.
81These differences lead to wide vari-
ability in treatment implementation and likely also result
in wide variations in outcomes in typical practice.
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Other chronic medical conditions,such as diabetes mel-
litus,utilize laboratory as well as symptom and function
measures in research settings that are readily usable in
clinical practice.To our knowledge,however,no system
to provide specific feedback or prompts related to symp-
toms,side effects,and recommended tactics (ie,when and
by how much to change the dose) during treatment has
been successfully used in a large clinical trial for patients
with psychiatric disorders.It is now clear that measure-
ment-based care (MBC) is an essential component to any
adaptive decision support system,allowing the physician
to individualize decisions about care for the patient based
on their progress and their ability to tolerate the medica-
tion.
5,82,83 The medication algorithms developed by our
group allow for sequential, adaptive MBC treatment
approaches including switching or augmenting antide-
pressant treatment in the case of patients who do not
fully remit following an adequate trial (at an adequate
dose and duration) of an antidepressant.
5,84,85 Both the
TMAP and STAR*D trials occurred in real-world clini-
cal settings and emphasized the importance of an MBC
approach—wherein the physician routinely assessed
depression symptom severity, adherence to treatment,
and side effects at each visit,and used this information
when following the medication treatment protocol.
5
Well-being therapy 
This is one of several psychotherapeutic strategies emerg-
ing from a growing interest in positive psychology.Well-
being therapy is based on Ryff’s multidimensional model
of psychological well-being,
86 covering six dimensions:
autonomy,personal growth,environmental mastery,pur-
pose in life,positive relations,and self-acceptance.Well-
being therapy as described by Fava and Ruini is a short-
term,psychotherapeutic strategy that extends over eight
sessions and emphasizes self-observation with the use of
a structured diary,as well as the interaction between the
therapist and patient.
87Well-being therapy is structured,
directive,and problem-oriented,with the goal of the ther-
apist being to lead the patient from an impaired level to
an optimal level of psychological well-being.
To date,well-being therapy has been used in several clin-
ical studies,both as a treatment for the residual phase of
affective disorders,
69 and also in terms of prevention of
recurrent depression.
66 In one study looking at preven-
tion of relapse in recurrent MDD,well-being therapy was
a specific part of a cognitive behavioral package that also
included cognitive behavioral treatment of residual
symptoms and lifestyle modification.Of 40 patients with
recurrent MDD who had been successfully treated with
antidepressants,after tapering and discontinuing medica-
tion,half were randomly assigned to the CBT package
and half to clinical management.Results showed a signif-
icantly lower relapse rate at a 2-year follow-up compared
with controls (25% vs 80%), with the CBT package
highly significant in delaying recurrence (P=0.003). It
should be noted that well-being therapy in this study was
only part of a package, and so it is not possible to say
what contribution it made to this finding.
Conclusions
Given the burden of major depressive disorder and the
fact that only about one third of patients respond to ini-
tial antidepressant treatment,further research is needed
to improve these suboptimal outcomes.
The goal for treatment of major depression has shifted
over time from mere response to full remission,partic-
ularly given the negative psychosocial and personal
implications of untreated residual symptoms.
In addition, given the recurrent nature of MDD, once
remission has been achieved,the challenge is to sustain
it.❏
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Estrategias terapéuticas para mejorar el
trastorno depresivo mayor y mantener la
remisión. 
El trastorno depresivo mayor (TDM) con frecuencia
es una enfermedad crónica y recurrente que afecta
a un gran número de personas en la población
general. En años recientes, el objetivo del trata-
miento del TDM ha cambiado desde la mera res-
puesta sintomática a la remisión total (por ej. sín-
tomas mínimos/ no residuales).
El reciente estudio STAR*D (Sequenced Treatment
Alternatives to Relieve Depression) demostró que
incluso con un tratamiento basado en la medición
sistemática, aproximadamente un tercio de los
pacientes alcanza la remisión completa después de
un ensayo terapéutico, y sólo dos tercios alcanzan
la remisión después de cuatro ensayos terapéuti-
cos. La depresión resistente al tratamiento (DRT) es
por lo tanto un problema común en el tratamiento
del TDM, y el 60% a 70% de todos los pacientes
reúne los criterios para DRT.  Considerando la
enorme carga de la enfermedad depresiva mayor,
el bajo porcentaje de recuperación completa per-
siste subóptimo. El siguiente artículo revisa algu-
nas estrategias terapéuticas actuales disponibles
para mejorar los porcentajes tanto de remisión
como del mantenimiento de ésta en el TDM.  
Stratégies thérapeutiques pour améliorer et
maintenir la rémission dans les troubles
dépressifs majeurs
Les troubles dépressifs majeurs (TDM) constituent
une maladie souvent chronique et récurrente qui
touche un grand nombre de sujets dans la popula-
tion générale. Ces dernières années, l’objectif du
traitement des TDM est passé d’une simple réponse
symptomatique à une rémission totale (c’est-à-dire,
symptômes résiduels absents ou minimaux).
L’étude récente STAR*D (Sequence Treatment
Alternatives to Relieve Depression) a montré que
même avec un traitement systématique basé sur
des mesures, à peu près 1/3 des patients sont en
rémission totale après un essai thérapeutique
contre 2/3 après 4 essais. La dépression résistance
au traitement (DRT) est donc un problème fré-
quent, avec 60 à 70 % de l’ensemble des patients
en présentant les critères. Compte tenu du handi-
cap énorme que représentent les TDM, le faible
taux de guérison totale reste sous-optimal. L’article
qui suit expose certaines stratégies thérapeutiques
actuelles capables d’améliorer et de maintenir les
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